Phase 1 study of intravenous administration of the chimeric adenovirus enadenotucirev in patients undergoing primary tumor resection

BACKGROUND: Enadenotucirev (formerly ColoAd1) is a tumor-selective chimeric adenovirus with demonstrated preclinical activity. This phase 1 Mechanism of Action study assessed intravenous (IV) delivery of enadenotucirev in patients with resectable colorectal cancer (CRC), non-small-cell lung cancer (...

Descripción completa

Detalles Bibliográficos
Autores principales: Garcia-Carbonero, Rocio, Salazar, Ramon, Duran, Ignacio, Osman-Garcia, Ignacio, Paz-Ares, Luis, Bozada, Juan M., Boni, Valentina, Blanc, Christine, Seymour, Len, Beadle, John, Alvis, Simon, Champion, Brian, Calvo, Emiliano, Fisher, Kerry
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2017
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5604344/
https://www.ncbi.nlm.nih.gov/pubmed/28923104
http://dx.doi.org/10.1186/s40425-017-0277-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5604344/
https://www.ncbi.nlm.nih.gov/pubmed/28923104
http://dx.doi.org/10.1186/s40425-017-0277-7

Ejemplares similares